Wuxi AppTec CoWUXIF 81 Net Current Asset Value is $2.04 as of Mar. 2026, which is 92% below its 10-year median of 26.60. GuruFocus rates WUXIF with a GF Score™ of 81/100 and a GF Value™ of $14.58 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 98 Medical Diagnostics & Research companies, Wuxi AppTec Co ranks worse than 72.45% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Wuxi AppTec Co's net current asset value per share for the quarter that ended in Mar. 2026 was $2.04.
The historical rank and industry rank for Wuxi AppTec Co's Net Current Asset Value or its related term are showing as below:
WUXIF'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 6.97 Med: 26.6 Max: 283.49
Current: 8.83
During the past 12 years, the highest Price-to-Net-Current-Asset-Value Ratio of Wuxi AppTec Co was 283.49. The lowest was 6.97. And the median was 26.60.
WUXIF's Price-to-Net-Current-Asset-Value is ranked worse than 72.45% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 3.83
vs WUXIF: 8.83
Wuxi AppTec Co (OTCPK:WUXIF) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Wuxi AppTec Co Net Current Asset Value Related Terms
Wuxi AppTec Co Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Wuxi AppTec Co's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WUXIF vs TMO, DHR, IDXX: Net Current Asset Value Comparison
For the Diagnostics & Research subindustry, Wuxi AppTec Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuxi AppTec Co Price-to-Net-Current-Asset-Value vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Wuxi AppTec Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Wuxi AppTec Co's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $2.04 mean?
Wuxi AppTec Co (WUXIF) has a Net Current Asset Value of $2.04 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Wuxi AppTec Co and its competitors. This is 92% below median its historical median of 26.60. Over the past decade, Wuxi AppTec Co's Net Current Asset Value has ranged from 6.97 to 283.49. According to the industry distribution chart, Wuxi AppTec Co ranks #71 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 72.4%.
Is Wuxi AppTec Co's Net Current Asset Value too high?
Wuxi AppTec Co's current Net Current Asset Value of $2.04 is 92% below median its 10-year median of 26.60. Over the past 10 years, this metric has ranged from a low of 6.97 to a high of 283.49. The Medical Diagnostics & Research industry median Net Current Asset Value is 3.83. Wuxi AppTec Co's value of $2.04 is 46.7% below this industry median. Based on the distribution chart, Wuxi AppTec Co ranks #71 out of 98 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Wuxi AppTec Co has a GF Score™ of 81/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Wuxi AppTec Co's Net Current Asset Value compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Wuxi AppTec Co ranks #71 out of 98 companies for Net Current Asset Value. This places Wuxi AppTec Co in the lower half of its industry. The industry median Net Current Asset Value is 3.83. Wuxi AppTec Co's value of $2.04 is 46.7% below this benchmark. Historically, Wuxi AppTec Co's own Net Current Asset Value has ranged from 6.97 to 283.49 over the past decade. While the company's 10-year median is 26.60 vs. the industry median of 3.83, Wuxi AppTec Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Diagnostics & Research company?
The median Net Current Asset Value among Medical Diagnostics & Research companies is 3.83, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wuxi AppTec Co's current Net Current Asset Value of $2.04 is 46.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Wuxi AppTec Co and its competitors. For the Medical Diagnostics & Research industry, the median Net Current Asset Value is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuxi AppTec Co's current Net Current Asset Value is $2.04, which is 92% below median its own 10-year median of 26.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuxi AppTec Co stock overvalued right now?
Based on GuruFocus' analysis, Wuxi AppTec Co (WUXIF) is currently considered Significantly Overvalued. The stock's GF Value™ is $14.58, compared to a current price of $21.19 — trading 45.3% above its estimated fair value. The current Net Current Asset Value is $2.04, which is 92% below median its 10-year median of 26.60 and 46.7% below the Medical Diagnostics & Research industry median of 3.83. Wuxi AppTec Co's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Wuxi AppTec Co (WUXIF), the current Net Current Asset Value is $2.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuxi AppTec Co (WUXIF) Overvalued in 2026?
Based on GuruFocus' analysis, Wuxi AppTec Co stock appears to be overvalued.
The current stock price of $21.19 is trading 45.3% above its estimated GF Value™ of $14.58.
GuruFocus considers Wuxi AppTec Co to be Significantly Overvalued.
Key valuation signals for WUXIF:
Net Current Asset Value: $2.04 (92% below median its 10-year median of 26.60)
GF Value™: $14.58 vs. price of $21.19 (45.3% above fair value)
Industry Position: 46.7% below the Medical Diagnostics & Research median (#71 of 98)
No single metric tells the full story. See the WUXIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuxi AppTec Co Ltd provides a portfolio of research and manufacturing services throughout the discovery, development, and manufacturing spectrum for small molecule drugs, development of computer software and databases as well as consulting services for combinatorial chemistry and pharmaceuticals. The services offered by the company include drug research and development testing, clinical research services, an end-to-end CRDMO platform for peptide, oligonucleotide, and small molecules, and integrated biology services and solutions for drug discovery. The company's reportable segments are WuXi Chemistry, which derives maximum revenue, WuXi Testing, WuXi Biology, and Others. Geographically, it derives key revenue from the United States of America, followed by PRC, Europe, and other regions.
81GF Score
Get the complete analysis for WUXIF
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WUXIF has been successfully added to your 
